PI3Kδ inhibition elicits anti-leukemic effects through Bim-dependent apoptosis

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• PI3Kδ inhibitors (PI3Kδi) are revolutionizing hematological malignancy treatment, showing clinical efficacy.
• Limited in vivo data exist on PI3Kδi mechanisms, hindering curative combination therapy development.
• Understanding PI3Kδi molecular mechanisms is vital for selecting effective treatment combinations.

Purpose of the Study:

• To characterize the molecular mechanisms of PI3Kδi-induced apoptosis in an in vivo model of chronic lymphocytic leukemia (CLL).
• To investigate the role of the pro-apoptotic protein Bim in PI3Kδi therapy.
• To evaluate PI3Kδi efficacy alone and in combination with anti-CD20 monoclonal antibody therapy in vivo.

Main Methods:

• In vitro and in vivo studies using murine (Emicro-Tcl1) and human (CLL) leukemia cells.
• Assessment of apoptosis induction and microenvironment-derived signaling disruption by PI3Kδi.
• Evaluation of therapeutic responses in Emicro-Tcl1-bearing animals and combination therapy with anti-CD20 therapy.
• Analysis of Bim protein expression and its role in PI3Kδi resistance using Bim knockout models.

Main Results:

• PI3Kδi induced significant apoptosis and disrupted microenvironment signaling in both murine and human CLL cells in vitro.
• PI3Kδi demonstrated therapeutic responses in vivo and enhanced anti-CD20 monoclonal antibody therapy efficacy.
• Therapeutic responses correlated with the upregulation of the pro-apoptotic protein Bim.
• Bim-deficient leukemias were resistant to PI3Kδi-induced apoptosis and combination therapy.

Conclusions:

• Bim-dependent apoptosis is a key in vivo therapeutic mechanism for PI3Kδ inhibitors in CLL.
• PI3Kδ inhibitors are effective alone and in combination therapies, mediated by Bim.
• Targeting PI3Kδ offers a promising strategy for treating hematological malignancies, particularly in combination regimens.